Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-21T16:47:42.840Z Has data issue: false hasContentIssue false
  • English
  • Français

Meta-Analysis of Randomized Trials on First Line and Adjunctive Levetiracetam

Published online by Cambridge University Press:  02 December 2014

Benjamin W. Y. Lo ,
Hmwe H. Kyu ,
Draga Jichici ,
Adrian M. Upton ,
Elie A. Akl  and
Maureen O. Meade
Benjamin W. Y. Lo*
Affiliation:
Division of Critical Care Medicine, Department of Clinical Edpiemiology & Biostatistics, McMaster University, Hamilton Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
Hmwe H. Kyu
Affiliation:
Division of Critical Care Medicine, Department of Clinical Edpiemiology & Biostatistics, McMaster University, Hamilton
Draga Jichici
Affiliation:
Division of Critical Care Medicine, Department of Clinical Edpiemiology & Biostatistics, McMaster University, Hamilton
Adrian M. Upton
Affiliation:
Division of Critical Care Medicine, Department of Clinical Edpiemiology & Biostatistics, McMaster University, Hamilton
Elie A. Akl
Affiliation:
Division of Critical Care Medicine, Department of Clinical Edpiemiology & Biostatistics, McMaster University, Hamilton Department of Medicine, University of Buffalo, Buffalo, NY, USA
Maureen O. Meade
Affiliation:
Division of Critical Care Medicine, Department of Clinical Edpiemiology & Biostatistics, McMaster University, Hamilton
*
Faculty of Health Sciences, McMaster University, Room 2U, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Context:

New evidence suggests that levetiracetam may be as effective as traditional agents, with better safety profile.

Objective:

To synthesize evidence regarding efficacy and tolerability of levetiracetam as first line, adjunctive or prophylactic antiepileptic agent.

Study Selection & Data Extraction:

Eligible studies were randomized controlled trials (RCTs) of levetiracetam used in adults with epilepsy. MEDLINE, EMBASE, CENTRAL, CINHAL, PAPERSFIRST, PROCEEDINGSFIRST, PROQUEST and conference proceedings identified studies (to September 30, 2010). Two investigators independently selected, appraised studies, collected and analyzed data.

Results:

Of ten eligible randomized trials, eight investigated adjunctive levetiracetam for refractory seizures, one as monotherapy for newly diagnosed seizures, one as monotherapy for prophylaxis. Eight RCTs of adjunctive levetiracetam were of moderate quality (GRADE criteria), with two showing lack of allocation concealment. Meta-analyses showed adjunctive levetiracetam was more effective than placebo in achieving at least 50% reduction of seizure frequency, when added to baseline antiepileptic regimen (pooled RR 2.15 [1.65,2.82], I2 = 45%, p value (heterogeneity) = 0.08, p value (overall effect) < 0.01). Likelihood of serious adverse events necessitating withdrawal from study was not significantly different between levetiracetam and control (pooled RR 1.37 [0.88,2.13], I2 = 0%, p value (heterogeneity) = 0.84, p value (overall effect) = 0.17). Subgroup analyses suggested similar effects across different dosages. Sensitivity analysis of studies with adequate concealment showed similar effects.

Conclusions:

Levetiracetam is an effective adjunctive agent for refractory epilepsy. More studies are needed to establish whether it is effective as monotherapy for newly diagnosed seizures, and for prophylaxis in traumatic brain injury.

Résumé:

Résumé:Contexte:

Selon des données récentes, le lévétiracétam serait aussi efficace que les agents traditionnels et bénéficierait d’un meilleur profil de sécurité.

Objectif:

Le but de cette étude était de faire la synthèse des données concernant l’efficacité et la tolérance du lévétiracétam comme traitement de première intention, comme médicament d’appoint ou comme agent antiépileptique prophylactique.

Choix des études et recueil des données:

Nous avons choisi les essais cliniques contrôlés randomisés évaluant le lévétiracétam chez des adultes épileptiques ainsi que les comptes rendus de conférences, publiés avant le 30 septembre 2010 dans les bases de données MEDLINE, EMBASE, CENTRAL, CINHAL, PAPERSFIRST, PROCEEDINGSFIRST et PROQUEST. Deux chercheurs ont choisi les essais cliniques de façon indépendante, les ont évalués et ont colligé et analysé les données.

Résultats:

Parmi les 10 essais cliniques randomisés éligibles, 8 portaient sur le lévétiracétam comme médicament d’appoint pour traiter l’épilepsie réfractaire au traitement, 1 comme médicament de première intention chez des patients au moment du diagnostic de l’épilepsie et 1 comme monothérapie en prophylaxie. Huit des essais cliniques randomisés évaluant le lévétiracétam comme médicament d’appoint étaient de qualité moyenne (critères GRADE), dont 2 où le traitement n’était pas en aveugle. Les méta-analyses ont montré que le lévétiracétam comme traitement d’appoint était plus efficace que le placebo pour diminuer d’au moins 50% la fréquence des crises quand il était ajouté au régime posologique de base (RR global 2,15 [1,65 - 2,82] ; 12 = 45%, p (hétérogénéité) = 0,08 ; p effet global < 0,01). La probabilité que des incidents thérapeutiques sérieux entraînent le retrait du patient de l’étude n’était pas significativement différente entre le groupe recevant le lévétiracétam et le groupe témoin (RR global 1,37 [0,88 - 2,13] ; 12 = 0% ; p (hétérogénéité) = 0,84 ; p effet global = 0,17). Selon les analyses de sous-groupes, les effets seraient les mêmes, quelle que soit la posologie. Les analyses de sensibilité des études bien menées à l’insu ont montré des effets similaires.

Conclusions:

Le lévétiracétam est un médicament d’appoint efficace dans l’épilepsie réfractaire au traitement. Il devra faire l’objet de nouvelles études pour établir son efficacité en monothérapie chez les patients dont le diagnostic est récent et en prophylaxie chez les patients qui ont subi un traumatisme crânien.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 3 , May 2011 , pp. 475 - 486
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1 Cereghino, J, Biton, V, Abou-Khalil, B, et al. Levetiracetam for partial seizures - results of a double-blind, randomized clinical trial. Neurology. 2000;55:236–42.CrossRefGoogle ScholarPubMed
2 French, J, Edrich, P, Cramer, J. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001;47:77–90.CrossRefGoogle ScholarPubMed
3 Leppik, I, Morrell, M, Godfroid, P, et al. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia. 2003;44(10):1350–2.Google Scholar
4 Otoul, C, Arrigo, C, van Rijckevorsel, , et al. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol. 2005;28(2):72–8.Google Scholar
5 Cramer, J, De Rue, K, Devinsky, O, et al. A systematic review of the behavioural effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. 2003;4:124–32.CrossRefGoogle ScholarPubMed
6 Higgins, JPT, Green, S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration [cited 2009 Sep 29]. Available from www.cochrane-handbook.org Google Scholar
7 Guyatt, G, Oxman, A, Vist, G, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–7.Google Scholar
8 Schunemann, H, Jaeschke, R, Cook, D, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006;174(5):605–14.Google Scholar
9 Daya, S. Funnel plots and publication bias - work in progress? Evidence-based Obstet and Gynecol. 2006;8:71–2.Google Scholar
10 Berkovic, S, Knowlton, R, Leroy, R, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007;69:1751–60.Google Scholar
11 Jones, K, Puccio, A, Harshman, K, et al. Levetiraectam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. 2008;25(4):e1–5.Google Scholar
12 Lim, D, Tarapore, P, Chan, E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J. Neurooncol. 2009;93(3):349–54.CrossRefGoogle ScholarPubMed
13 Milligan, T, Hurwitz, S, Bromfield, E, et al. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008;71:665–9.CrossRefGoogle ScholarPubMed
14 Noachtar, S, Andermann, E, Meyvisch, P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70:607–16.CrossRefGoogle ScholarPubMed
15 Steinhoff, B, Somerville, E, van Paesschen, W, et al. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res. 2007;76(1):6–14.CrossRefGoogle ScholarPubMed
16 Szaflarski, J, Sangha, K, Lindsell, C, et al. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010; 12(2):165–72.Google Scholar
17 Brodie, M, Perucca, E, Ryvlin, P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402–8.CrossRefGoogle ScholarPubMed
18 Ben-Menachem, E, Falter, U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 2000;41(10):1276–83.Google Scholar
19 Shorvon, S, Löwenthal, A, Janz, D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia. 2000;41(9):1179–86.Google Scholar
20 Peltola, J, Coetzee, C, Jimenez, F, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebocontrolled trial. Epilepsia. 2009;50(3):406–14.Google Scholar
21 Xiao, Z, Li, J-M, Wang, X-F, et al. Efficacy and safety of levetiracetam (3000 mg/day) as an adjunctive therapy in Chinese patients with refractory partial seizures. Eur Neurol. 2009;61: 233–9.CrossRefGoogle Scholar
22 Wu, X-Y, Hong, Z, Wu, X, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia. 2009;50(3):398–405.Google Scholar
23 Tsai, J-J, Yen, D-J, Hsih, M-S, et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, doubleblind, placebo-controlled study. Epilepsia. 2006;47(1):72–81.Google Scholar
24 Betts, T, Waegemans, T, Crawford, P. A multicenter, double-blind, randomized, parallel group study to evaluate to the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80–7.CrossRefGoogle Scholar